Vaccine maker BioNTech to set up regional headquarters, manufacturing site in Singapore
BioNTech s Singapore office is expected to be operational in 2023 and will create at least 80 jobs. Photo: Reuters The Straits Times The Straits Times
BioNTech, the vaccine maker that has partnered with Pfizer on its Covid-19 shot, will be designating Singapore as its regional headquarters for South-east Asia, and will set up an mRNA manufacturing facility here.
It plans to open its Singapore office and start the construction of the manufacturing facility in 2021, subject to planning approval. The site is expected to be operational in 2023 and will create at least 80 jobs, the German company said on Monday (May 10).
BioNTech to establish its first regional hub for Asia Pacific in Singapore Details
Expected to be operationally ready by 2023, the facility is expected to create 80 jobs for locals.
Germany pharmaceutical company, BioNTech, maker of the Pfizer-BioNTech which currently protects from three Covid-19 variants, is setting up its first Asia Pacific office in Singapore creating employment opportunities for people in the Republic.
The move, announced on 10 May, is part of the company’s bid to expand its global footprint in Asia through this SEA regional headquarters.
In addition, the German company is also looking to establish an mRNA manufacturing facility here. The new facility, supported by the Singapore Economic Development Board (EDB), will provide regional and global supply capacity of its growing pipeline of mRNA-based product candidates, as well as a rapid response production capability to address potential pandemic threats in the region.
2021-05-10 14:35:39 GMT2021-05-10 22:35:39(Beijing Time) Xinhua English
BERLIN, May 10 (Xinhua) German biotechnology company BioNTech SE said on Monday that it would establish its first hub in the Asia-Pacific region by establishing a regional headquarters in Singapore.
BioNTech also announced that it will build a fully integrated mRNA manufacturing facility in Singapore, supported by the Singapore Economic Development Board (EDB). The facility would be operational in 2023, according to the company. Having multiple nodes in our production network is an important strategic step in building out our global footprint and capabilities, said Ugur Sahin, chief executive officer (CEO) and co-founder of BioNTech, in a statement.
Published: May 10, 2021
BioNTech to establish first regional hub in Asia Pacific region in Singapore
Planned state-of-the-art manufacturing site will support global supply of mRNA-based vaccines and therapeutics and provide a rapid response capability for south east Asia against potential future pandemic threats
Expansion plan supported by the Singapore Economic Development Board (EDB)
MAINZ, GERMANY, May 10, 2021
BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced plans to expand its global footprint to Asia with the establishment of its Regional Headquarters for south east Asia in Singapore. In addition to selecting Singapore as its future regional headquarters, BioNTech plans to establish a fully integrated mRNA manufacturing facility in Singapore with support from the Singapore Economic Development Board. The new facility will provide regional and global supply capacity of BioNTech’s growing pipeline of mRNA-based product candidates, a
BioNTech to produce mRNA vaccines in Singapore, its new regional headquarters Toggle share menu
Advertisement The manufacturing facility in Singapore could be operational as early as 2023.
German biotechnology firm BioNTech, which partnered Pfizer to develop a COVID-19 vaccine using messenger RNA (mRNA) technology, will set up its regional headquarters in Singapore, along with a manufacturing facility. Brandon Tanoto with more. 2 related media assets (image or videos) available. Click to see the gallery.
10 May 2021 11:26PM) Share this content
Bookmark
SINGAPORE: German biotechnology firm BioNTech, which partnered Pfizer to develop a COVID-19 vaccine using messenger RNA (mRNA) technology, will set up its regional headquarters in Singapore, along with a manufacturing facility.